|
WO2021024207A1
|
|
Cellular compositions comprising viral vectors and methods of treatment
|
|
WO2020234450A1
|
|
Functional recovery from cerebral infarction
|
|
WO2020157660A1
|
|
Method for treating or preventing gastrointestinal bleeding
|
|
WO2020141483A1
|
|
Method for improving visual acuity
|
|
WO2020141473A1
|
|
Method for treating lower back pain
|
|
WO2020089411A1
|
|
Expansion of hematopoietic stem cells
|
|
KR20200088445A
|
|
Cell composition and treatment method I
|
|
US2020325450A1
|
|
Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
|
|
EP3292199A1
|
|
Potency assay
|
|
US2016375100A1
|
|
Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
|
|
KR20170098862A
|
|
Prevention of progressive heart failure
|
|
SG10202008024VA
|
|
Method for Treating Heart Failure
|
|
AU2015268673A1
|
|
Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
|
|
AU2015264932A1
|
|
Mesenchymal stem cells expressing TNF-alpha receptor
|
|
AU2015252160A1
|
|
Mesenchymal stem cells and uses therefor
|
|
KR20170007854A
|
|
Treatment of immune disorders
|
|
AU2015201881A1
|
|
Use of mesenchymal stem cells for treating genetic diseases and disorders
|
|
CA2933620A1
|
|
Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
|
|
AU2012205269A1
|
|
Mesenchymal stem cells and uses therefor
|
|
AU2012268078A1
|
|
Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
|
